Back to Biomarkers List
Associated Genetic Biomarkers
Chromodomain helicase DNA binding protein 4 (CHD4) is a gene that encodes a protein that is the main component of the nucleosome remodeling and deacetylase complex and plays an important role in epigenetic transcriptional repression. Missense mutations, synonymous mutations, nonsense mutations, inframe deletions, frameshift deletions, and frameshift insertions are observed in cancers such as stomach cancer, endometrial cancer, and colon cancer.
CHD4 is altered in 3.69% of all cancers with breast invasive ductal carcinoma, colon adenocarcinoma, cutaneous melanoma, bladder urothelial carcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in CHD4 are CHD4 Mutation (3.09%), CHD4 Amplification (0.99%), CHD4 R1162W (0.09%), CHD4 R975H (0.09%), and CHD4 R1105W (0.28%) .
CHD4 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains CHD4 status as an inclusion criterion, 1 is phase 1 (0 open).
Trials with CHD4 status in the inclusion eligibility criteria most commonly target bladder carcinoma, breast carcinoma, colorectal carcinoma, head and neck carcinoma, and lymphoma .
The most frequent alteration to serve as an inclusion eligibility criterion is CHD4 Mutation .
Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in trials with CHD4 as an inclusion criteria .
Significance of CHD4 in Diseases
Bladder Carcinoma +
Colorectal Carcinoma +
Head And Neck Carcinoma +
Malignant Solid Tumor +
Breast Carcinoma +
Anaplastic Astrocytoma +
Ovarian Carcinoma +
Non-Small Cell Lung Carcinoma +
CHD4 is altered in 2.22% of non-small cell lung carcinoma patients .
CHD4 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CHD4 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) .
Pancreatic Carcinoma +
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.